Furthermore, we showed that CRNDE targeted directly at EZH2, SUZ12, and SUV39H1 in HCC and promoted HCC progression by mediating their inhibition on various tumor suppressor genes, including CELF2 and LATS2. The gene discussed is LATS2; the disease is hepatocellular carcinoma.